109881 Aventis.
作者信息
Ojima Iwao, Geney Raphaël
机构信息
Department of Chemistry, Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USA.
出版信息
Curr Opin Investig Drugs. 2003 Jun;4(6):737-40.
PMID:12901234
Abstract
109881 is an orally and intravenously active taxoid in development by Aventis Pharma (formerly Rhône-Poulenc Rorer) as a potential treatment for a variety of taxoid-resistant solid tumors, such as brain and lung cancers. As of April 2000, the compound was in phase IIa trials in the US, France, Belgium and Germany. Phase II trials were ongoing in May 2001, and the company was evaluating an oral formulation at this time.
摘要
相似文献
1
109881 Aventis.
Curr Opin Investig Drugs. 2003 Jun;4(6):737-40.
2
BMS-247550 Bristol-Myers Squibb/GBF.百时美施贵宝公司/GBF的BMS - 247550
Curr Opin Investig Drugs. 2003 Jun;4(6):746-56.
3
BAY-43-9006 Bayer/Onyx.BAY - 43 - 9006（拜耳/奥尼克斯公司）
Curr Opin Investig Drugs. 2003 Jun;4(6):757-63.
4
CMT-3. CollaGenex.
Curr Opin Investig Drugs. 2003 Dec;4(12):1460-7.
5
MEN-10755. Menarini.MEN - 10755。美纳里尼公司。
Curr Opin Investig Drugs. 2003 Dec;4(12):1473-8.
6
Lapatinib ditosylate GlaxoSmithKline.
IDrugs. 2003 Sep;6(9):886-93.
7
Lerisetron. FAES.
Curr Opin Investig Drugs. 2003 Jul;4(7):874-7.
8
ONO-2506. Ono.
Curr Opin Investig Drugs. 2003 Jul;4(7):863-7.
9
Ganstigmine. Chiesi.加兰他敏。基耶西公司。
Curr Opin Investig Drugs. 2003 Jul;4(7):868-73.
10
Cilengitide Merck.西仑吉肽 默克公司。
Curr Opin Investig Drugs. 2003 Jun;4(6):741-5.
引用本文的文献
1
Tubulin-interactive natural products as anticancer agents.作为抗癌剂的微管相互作用天然产物。
J Nat Prod. 2009 Mar 27;72(3):507-15. doi: 10.1021/np800568j.
Zotero 插件